[1]穆大明.厄贝沙坦氢氯噻嗪与福辛普利治疗原发性高血压的疗效观察[J].医学信息,2019,32(03):151-152.[doi:10.3969/j.issn.1006-1959.2019.03.049]
　MU Da-ming.Efficacy of Irbesartan Hydrochlorothiazide and Fosinopril in the Treatment of Essential Hypertension[J].Journal of Medical Information,2019,32(03):151-152.[doi:10.3969/j.issn.1006-1959.2019.03.049]
点击复制

厄贝沙坦氢氯噻嗪与福辛普利治疗原发性高血压的疗效观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年03期
页码:
151-152
栏目:
药物与临床
出版日期:
2019-02-01

文章信息/Info

Title:
Efficacy of Irbesartan Hydrochlorothiazide and Fosinopril in the Treatment of Essential Hypertension
文章编号:
1006-1959（2019）03-0151-02
作者:
穆大明
（葫芦岛市第二人民医院心内科，辽宁 葫芦岛 125000）
Author(s):
MU Da-ming
(Department of Cardiology,the Second People's Hospital,Huludao 125000,Liaoning,China)
关键词:
厄贝沙坦氢氯噻嗪; 福辛普利; 原发性高血压; 不良反应
Keywords:
Irbesartan hydrochlorothiazide; Fosinopril; Essential hypertension; Adverse reactions
分类号:
R544
DOI:
10.3969/j.issn.1006-1959.2019.03.049
文献标志码:
A
摘要:
目的 探讨厄贝沙坦氢氯噻嗪治疗原发性高血压的效果。方法 选取2017年1月~12月我院收治的120例原发性高血压患者作为研究对象，按照随机数字表法分为对照组和实验组，每组60例。对照组给予福辛普利治疗，实验组给予厄贝沙坦氢氯噻嗪治疗，观察两组的治疗总有效率、血压改善情况及不良反应发生率。结果 实验组患者的临床总有效率为96.67%，优于对照组的75.00%；实验组患者血压水平改善情况更为理想，实验组不良反应发生率为5.00%，低于对照组的15.00%，差异具有统计学的意义（P＜0.05）。结论 厄贝沙坦氢氯噻嗪治疗原发性高血压疾病疗效确切且较安全，可以作为治疗原发性高血压的首选药物。
Abstract:
Objective To investigate the effect of irbesartan hydrochlorothiazide in the treatment of essential hypertension.Methods 120 patients with essential hypertension admitted in our hospital from January to December 2017 were selected as study subjects.According to the random digital table method, they were divided into the control group and the experimental group two groups,60 cases in each group.The control group was treated with fosinopril and the experimental group with irbesartan hydrochlorothiazide.The total effective rate, the improvement of blood pressure and the incidence of adverse reactions were observed.Results The total effective rate of the patients in the experimental group was 96.67%, which was better than that in the control group 75.00%;The incidence of adverse reactions in the experimental group was 5.00%,which was lower than that in the control group 15.00%,the difference was statistically significant(P<0.05).Conclusion Irbesartan hydrochlorothiazide is effective and safe in the treatment of essential hypertension.It can be used as the first choice for the treatment of essential hypertension.

参考文献/References:


[1]阮晓豪,符晓红,徐瑞,等.厄贝沙坦氢氯噻嗪复方片治疗老年原发陛高血压 30 例临床观察[J].医学信息,2014,27(17):437.
[2]康文慧.厄贝沙坦氢氯噻嗪和福辛普利治疗原发性高血压疗效比较[J].中西医结合心血管病电子杂志,2014(12):223-224.
[3]孙丽琴,马长江.厄贝沙坦联合氢氯噻嗪治疗老年原发性高血压的疗效观察[J].临床合理用药杂志2016,9(17):26-27.
[4]郝双.厄贝沙坦联合氢氯噻嗪治疗老年原发性高血压的临床观察[J].中国医药科学,2014,33(10):97-99.
[5]李雷,杨荣礼,卢海龙,等.厄贝沙坦氢氯噻嗪对老年高血压患者尿微量白蛋白与尿肌酐比值的影响[J]. 中国循证心血管医学杂志,2016,8(3):320-322.
[6]许晶.厄贝沙坦氢氯噻嗪和福辛普利治疗原发性高血压疗效比较[J].中国卫生标准管理,2017,8(10):81-83.

更新日期/Last Update: 2019-02-25